What's new in diagnostic testing and treatment approaches for mycoplasma pneumoniae infections in children?

Advances in Experimental Medicine and Biology

Volumn 719, Issue , 2011, Pages 47-57

  Waites, Ken B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACTERIUM ANTIBODY; CEFTRIAXONE; CLARITHROMYCIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; LEVOFLOXACIN; MACROLIDE; MINOCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOLITHROMYCIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; BACTERIUM CULTURE; BACTERIUM DETECTION; CHILD; COMMON COLD; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; HOARSENESS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN DEFICIENCY; LYMPHOCYTE ACTIVATION; MOLECULAR DIAGNOSIS; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; NOSE CONGESTION; NUCLEIC ACID AMPLIFICATION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; SORE THROAT; STEVENS JOHNSON SYNDROME; THORAX RADIOGRAPHY;

ANTI-BACTERIAL AGENTS; CHILD; DIAGNOSTIC TESTS, ROUTINE; HUMANS; MYCOPLASMA INFECTIONS; MYCOPLASMA PNEUMONIAE;

EID: 83455219846     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0204-6_5     Document Type: Article

References (41)

1. Atkinson TP, Boppana S, Theos A, CLements LS, Xiao L, Waites K. Stevens-Johnson Syndrome in a patient with macrolide-resistant Mycoplasma pneumoniae. Pediatrics 2011;127:e1605-1609.
2. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17(4):697-728. (Pubitemid 39372513)
3. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 1993;17 Suppl 1:S37-46. (Pubitemid 23227104)
4. Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995;14(6):471-7.
5. Korppi M, Heiskanen-Kosma T, Kleemola M. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Respirology 2004;9(1):109-14. (Pubitemid 38647779)
6. Layani-Milon MP, Gras I, Valette M, Luciani J, Stagnara J, Aymard M, et al. Incidence of upper respiratory tract Mycoplasma pneumoniae infections among outpatients in Rhone-Alpes, France, during five successive winter periods. J Clin Microbiol 1999;37(6):1721-6. (Pubitemid 29235213)
7. Esposito S, Blasi F, Bosis S, Droghetti R, Faelli N, Lastrico A, et al. Aetiology of acute pharyngitis: the role of atypical bacteria. J Med Microbiol 2004;53(Pt 7):645-51. (Pubitemid 38932363)
8. Esposito S, Bosis S, Begliatti E, Droghetti R, Tremolati E, Tagliabue C, et al. Acute tonsillopharyngitis associated with atypical bacterial infection in children: natural history and impact of macrolide therapy. Clin Infect Dis 2006;43(2):206-9.
9. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 2008;32(6):956-73.
10. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol 2008;3(6):635-48.
11. Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci USA 2006;103(17):6724-9.
12. Dallo SF, Baseman JB. Intracellular DNA replication and long-term survival of pathogenic mycoplasmas. Microb Pathog 2000;29(5):301-9.
13. Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW. Increased susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J Med 1986;80(4):590-4. (Pubitemid 16035574)
14. Waites KB, Simecka JW, Talkington DF, Atkinson TP. Pathogensis of Mycoplasma pneumoniae infections: adaptive immunity, innate immuinity, cell biology and virulence factors. In: Suttorp N, Welte T, Marre R, editors. Community-acquired pneumonia. Basel, Switzerland: Burkhauser Verlag; 2007. p. 183-99.
15. Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother 2010;16(3):162-9.
16. Loens K, Goossens H, Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current satus of diagnostic methods. Eur J Clin Microbiol Infect Dis 2010;29:1055-69.
17. Beersma MF, Dirven K, Van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol 2005;43(5):2277-85. (Pubitemid 40656241)
18. Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol 2004;11(5):862-7. (Pubitemid 39280590)
19. Ozaki T, Nishimura N, Ahn J, Watanabe N, Muto T, Saito A, et al. Utility of a rapid diagnosis kit for Mycoplasma pneumoniae pneumonia in children, and the antimicrobial susceptibility of the isolates. J Infect Chemother 2007;13(4):204-7. (Pubitemid 47313113)
20. Daxboeck F, Khanakah G, Bauer C, Stadler M, Hofmann H, Stanek G. Detection of Mycoplasma pneumoniae in serum specimens from patients with mycoplasma pneumonia by PCR. Int J Med Microbiol 2005;295(4): 279-85. (Pubitemid 41020801)
21. Dumke R, Jacobs E. Comparison of commercial and in-house real-time PCR assays used for detection of Mycoplasma pneumoniae. J Clin Microbiol 2009;47(2):441-4.
22. Loens K, Mackay WG, Scott C, Goossens H, Wallace P, Ieven M. A multicenter pilot external quality assessment programme to assess the quality of molecular detection of Chlamydophila pneumoniae and Mycoplasma pneumoniae. J Microbiol Methods 2010;82(2):131-5.
23. McCracken GH, Jr. Current status of antibiotic treatment for Mycoplasma pneumoniae infections. Pediatr Infect Dis 1986;5(1):167-71.
24. Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998;17(10):865-71. (Pubitemid 28506406)
25. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased Macrolide Resistance of Mycoplasma pneumoniae in Pediatric Patients with Community-Acquired Pneumonia. Antimicrob Agents Chemother 2008;52(1):348-50.
26. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006;50(2):709-12. (Pubitemid 43190986)
27. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004;48(12):4624-30. (Pubitemid 39577663)
28. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23 S rRNA gene mutation. Antimicrob Agents Chemother 2005;49(6):2302-6. (Pubitemid 40734458)
29. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009;53(5):2158-9.
30. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother 2009;53(5):2160-2.
31. Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009;64(1):52-8.
32. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother 2008;52(10):3542-9.
33. Miyashita N, Maruyama T, Kobayashi T, Kobayashi H, Taguchi O, Kawai Y, et al. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother.
34. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr Infect Dis J 2009;28(8): 693-6.
35. Dumke R, Schurwanz N, Lenz M, Schuppler M, Luck C, Jacobs E. Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach. J Clin Microbiol 2007;45(8):2726-30. (Pubitemid 47295516)
36. Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008;8(3):286-91.
37. Duffy LB, Crabb DM, Bing X, Waites KB. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J Antimicrob Chemother 2003;52(3):527-8. (Pubitemid 37120745)
38. Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA, Jr., et al. Levofloxacin Pharmacokinetics in Children. J Clin Pharmacol 2005;45(2):153-60. (Pubitemid 40490438)
39. Smilack JD, Burgin WW, Jr., Moore WL, Jr., Sanford JP. Mycoplasma pneumoniae pneumonia and clindamycin therapy. Failure to demonstrate efficacy. Jama 1974;228(6):729-31.
40. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 2009;53(5):2139-41.
41. Talkington DF, Waites KB, Schwartz SB, Besser RE. Emerging from obscurity: understanding pulmonary and exrrapulmonary syndromes, pathogenesis, and epidemiology of human Mycoplasma pneumoniae infections. In: Scheld WM, Craig WA, Hughes JM, editors. Emerging Infections 5. Washington, D.C.: American Society for Microbiology; 2001. p. 57-84.